Know what you own
If leronlimab can definitively halt metastasis and convert immunologically "cold" tumors into "hot" ones, it would represent one of the largest disruptions in modern oncology, shifting billions of dollars in market value and fundamentally altering cancer survival rates.Because metastasis causes over 90% of cancer-related deaths, and "cold" tumors aggressively evade the immune system, a drug that successfully solves both challenges would basically be the Holy Grail in oncology.
In small trials and retrospectively leronlimab has signaled that it does both, Cytodyn is now in the process of prospectively proving it.
This is exactly the reason why I purchased more shares today!
Everyone has to do their own due diligence but what I described is already listed in the peer reviewed publications on leronlimab.
If leronlimab can definitively halt metastasis and convert immunologically "cold" tumors into "hot" ones, it would represent one of the largest disruptions in modern oncology, shifting billions of dollars in market value and fundamentally altering cancer survival rates.Because metastasis causes over 90% of cancer-related deaths, and "cold" tumors aggressively evade the immune system, a drug that successfully solves both challenges would basically be the Holy Grail in oncology.
In small trials and retrospectively leronlimab has signaled that it does both, Cytodyn is now in the process of prospectively proving it.
This is exactly the reason why I purchased more shares today!
Everyone has to do their own due diligence but what I described is already listed in the peer reviewed publications on leronlimab.
21
